-
1
-
-
20044378182
-
The Fontan circulation
-
Gewillig M. The Fontan circulation. Heart 2005; 91: 839-846.
-
(2005)
Heart
, vol.91
, pp. 839-846
-
-
Gewillig, M.1
-
2
-
-
34748845815
-
The Fontan procedure: Contemporary techniques have improved long-term outcomes
-
d'Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 2007; 116: I157-I164.
-
(2007)
Circulation
, vol.116
-
-
d'Udekem, Y.1
Iyengar, A.J.2
Cochrane, A.D.3
-
3
-
-
0030866886
-
Fontan operation in five hundred consecutive patients: Factors influencing early and late outcome
-
Gentles TL, Mayer JE Jr., Gauvreau K, et al. Fontan operation in five hundred consecutive patients: Factors influencing early and late outcome. J Thorac Cardiovasc Surg 1997; 114: 376-391.
-
(1997)
J Thorac Cardiovasc Surg
, vol.114
, pp. 376-391
-
-
Gentles, T.L.1
Mayer Jr., J.E.2
Gauvreau, K.3
-
4
-
-
0030852544
-
Functional outcome after the Fontan operation: Factors influencing late morbidity
-
discussion 404-405
-
Gentles TL, Gauvreau K, Mayer JE Jr., et al. Functional outcome after the Fontan operation: Factors influencing late morbidity. J Thorac Cardiovasc Surg 1997; 114: 392-403; discussion 404-405.
-
(1997)
J Thorac Cardiovasc Surg
, vol.114
, pp. 392-403
-
-
Gentles, T.L.1
Gauvreau, K.2
Mayer Jr., J.E.3
-
5
-
-
0030220666
-
Improved early morbidity and mortality after Fontan operation: The Mayo Clinic experience, 1987 to 1992
-
Cetta F, Feldt RH, O'Leary PW, et al. Improved early morbidity and mortality after Fontan operation: The Mayo Clinic experience, 1987 to 1992. J Am Coll Cardiol 1996; 28: 480-486.
-
(1996)
J Am Coll Cardiol
, vol.28
, pp. 480-486
-
-
Cetta, F.1
Feldt, R.H.2
O'Leary, P.W.3
-
6
-
-
22144454676
-
Long-term results of the Fontan operation for double-inlet left ventricle
-
Earing MG, Cetta F, Driscoll DJ, et al. Long-term results of the Fontan operation for double-inlet left ventricle. Am J Cardiol 2005; 96: 291-298.
-
(2005)
Am J Cardiol
, vol.96
, pp. 291-298
-
-
Earing, M.G.1
Cetta, F.2
Driscoll, D.J.3
-
7
-
-
0038649817
-
The modified Fontan procedure: Early and late results in 132 adult patients
-
Burkhart HM, Dearani JA, Mair DD, et al. The modified Fontan procedure: early and late results in 132 adult patients. J Thorac Cardiovasc Surg 2003; 125: 1252-1259.
-
(2003)
J Thorac Cardiovasc Surg
, vol.125
, pp. 1252-1259
-
-
Burkhart, H.M.1
Dearani, J.A.2
Mair, D.D.3
-
8
-
-
0031955639
-
Protein-losing enteropathy after the Fontan operation: An international multicenter study. PLE study group
-
Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: An international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998; 115: 1063-1073.
-
(1998)
J Thorac Cardiovasc Surg
, vol.115
, pp. 1063-1073
-
-
Mertens, L.1
Hagler, D.J.2
Sauer, U.3
Somerville, J.4
Gewillig, M.5
-
9
-
-
37349037210
-
Long-Term Survival, Modes of Death, and Predictors of Mortality in Patients With Fontan Surgery
-
Khairy P, Fernandes SM, Mayer JE Jr., et al. Long-Term Survival, Modes of Death, and Predictors of Mortality in Patients With Fontan Surgery. Circulation 2008; 117: 85-92.
-
(2008)
Circulation
, vol.117
, pp. 85-92
-
-
Khairy, P.1
Fernandes, S.M.2
Mayer Jr., J.E.3
-
10
-
-
6344239028
-
Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure
-
Mitchell MB, Campbell DN, Ivy D, et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg 2004; 128: 693-702.
-
(2004)
J Thorac Cardiovasc Surg
, vol.128
, pp. 693-702
-
-
Mitchell, M.B.1
Campbell, D.N.2
Ivy, D.3
-
11
-
-
0038078913
-
Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation
-
Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003; 107: 3204-3208.
-
(2003)
Circulation
, vol.107
, pp. 3204-3208
-
-
Khambadkone, S.1
Li, J.2
de Leval, M.R.3
Cullen, S.4
Deanfield, J.E.5
Redington, A.N.6
-
12
-
-
0036737931
-
The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease
-
Schulze-Neick I, Li J, Reader JA, Shekerdemian L, Redington AN, Penny DJ. The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease. J Thorac Cardiovasc Surg 2002; 124: 435-441.
-
(2002)
J Thorac Cardiovasc Surg
, vol.124
, pp. 435-441
-
-
Schulze-Neick, I.1
Li, J.2
Reader, J.A.3
Shekerdemian, L.4
Redington, A.N.5
Penny, D.J.6
-
13
-
-
0036920084
-
The role of plasma endothelin in the Fontan circulation
-
Yamagishi M, Kurosawa H, Hashimoto K, Nomura K, Kitamura N. The role of plasma endothelin in the Fontan circulation. J Cardiovasc Surg 2002; 43: 793-797.
-
(2002)
J Cardiovasc Surg
, vol.43
, pp. 793-797
-
-
Yamagishi, M.1
Kurosawa, H.2
Hashimoto, K.3
Nomura, K.4
Kitamura, N.5
-
14
-
-
0033653706
-
Endothelin receptor antagonists: Current status and perspectives
-
Clozel M. Endothelin receptor antagonists: Current status and perspectives. J Cardiovasc Pharmacol 2000; 35: S65-S68.
-
(2000)
J Cardiovasc Pharmacol
, vol.35
-
-
Clozel, M.1
-
15
-
-
0344406959
-
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
-
Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 372-382
-
-
Barst, R.J.1
Ivy, D.2
Dingemanse, J.3
-
16
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
-
(2002)
N Engl J Med
, vol.346
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
-
17
-
-
0035432179
-
-
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800-812
-
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800-812.
-
-
-
-
18
-
-
45549102473
-
The six-minute walk test: Normal values for children of 4-11 years of age
-
Lammers AE, Hislop AA, Flynn Y, Haworth SG. The six-minute walk test: Normal values for children of 4-11 years of age. Arch Dis Child 2008; 93: 464-468.
-
(2008)
Arch Dis Child
, vol.93
, pp. 464-468
-
-
Lammers, A.E.1
Hislop, A.A.2
Flynn, Y.3
Haworth, S.G.4
-
19
-
-
27744444638
-
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
-
Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025-1030.
-
(2005)
Thorax
, vol.60
, pp. 1025-1030
-
-
Sitbon, O.1
McLaughlin, V.V.2
Badesch, D.B.3
-
20
-
-
33750344748
-
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions
-
Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheumatic Dis 2006; 65: 1336-1340.
-
(2006)
Ann Rheumatic Dis
, vol.65
, pp. 1336-1340
-
-
Denton, C.P.1
Humbert, M.2
Rubin, L.3
Black, C.M.4
-
21
-
-
50249155984
-
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
-
Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheumatic Dis 2008; 67: 1222-1228.
-
(2008)
Ann Rheumatic Dis
, vol.67
, pp. 1222-1228
-
-
Denton, C.P.1
Pope, J.E.2
Peter, H.H.3
-
22
-
-
20344374050
-
Effects of long-term bosentan in children with pulmonary arterial hypertension
-
Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
-
(2005)
J Am Coll Cardiol
, vol.46
, pp. 697-704
-
-
Rosenzweig, E.B.1
Ivy, D.D.2
Widlitz, A.3
-
23
-
-
33746206340
-
Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study
-
Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
-
(2006)
Circulation
, vol.114
, pp. 48-54
-
-
Galie, N.1
Beghetti, M.2
Gatzoulis, M.A.3
-
24
-
-
33646255654
-
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
-
Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 2049-2056
-
-
Barst, R.J.1
Langleben, D.2
Badesch, D.3
-
25
-
-
34249854139
-
A review of pulmonary arterial hypertension: Role of ambrisentan
-
Barst RJ. A review of pulmonary arterial hypertension: Role of ambrisentan. Vasc Health Risk Manag 2007; 3: 11-22.
-
(2007)
Vasc Health Risk Manag
, vol.3
, pp. 11-22
-
-
Barst, R.J.1
-
26
-
-
33846247928
-
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan
-
Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26: 63-69.
-
(2007)
J Heart Lung Transplant
, vol.26
, pp. 63-69
-
-
Benza, R.L.1
Mehta, S.2
Keogh, A.3
Lawrence, E.C.4
Oudiz, R.J.5
Barst, R.J.6
-
27
-
-
21044449937
-
Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study
-
Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-3280.
-
(2005)
Circulation
, vol.111
, pp. 3274-3280
-
-
Humpl, T.1
Reyes, J.T.2
Holtby, H.3
Stephens, D.4
Adatia, I.5
-
28
-
-
23744452438
-
Bosentan induces clinical, exercise and hemodynamic improvement in a pretransplant patient with plastic bronchitis after Fontan operation
-
Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pretransplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005; 24: 1174-1176.
-
(2005)
J Heart Lung Transplant
, vol.24
, pp. 1174-1176
-
-
Apostolopoulou, S.C.1
Papagiannis, J.2
Rammos, S.3
-
29
-
-
0037326862
-
Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure
-
Miyaji K, Nagata N, Miyamoto T, Kitahori K. Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure. J Thorac Cardiovasc Surg 2003; 125: 437-439.
-
(2003)
J Thorac Cardiovasc Surg
, vol.125
, pp. 437-439
-
-
Miyaji, K.1
Nagata, N.2
Miyamoto, T.3
Kitahori, K.4
-
30
-
-
33750035793
-
Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome
-
Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006; 132: 1232-1233.
-
(2006)
J Thorac Cardiovasc Surg
, vol.132
, pp. 1232-1233
-
-
Haseyama, K.1
Satomi, G.2
Yasukochi, S.3
Matsui, H.4
Harada, Y.5
Uchita, S.6
-
31
-
-
33751176882
-
Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan
-
Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006; 82: E39-e40.
-
(2006)
Ann Thorac Surg
, vol.82
-
-
Uzun, O.1
Wong, J.K.2
Bhole, V.3
Stumper, O.4
-
32
-
-
46849112004
-
Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients
-
Giardini A, Balducci A, Specchia S, Gargiulo G, Bonviccini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29: 1681-1687.
-
(2008)
Eur Heart J
, vol.29
, pp. 1681-1687
-
-
Giardini, A.1
Balducci, A.2
Specchia, S.3
Gargiulo, G.4
Bonviccini, M.5
Picchio, F.M.6
|